Noncirrhotic portal hypertension and didanosine: A re-analysis

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 154-155

  Young, Jim ^a   Klein, Marina B ^c   Ledergerber, Bruno ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; STAVUDINE; TENOFOVIR; ZALCITABINE;

COHORT ANALYSIS; DIABETES MELLITUS; DRUG EXPOSURE; EDUCATIONAL STATUS; ETHNICITY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS C; HUMAN; LETTER; LIPOATROPHY; LOGISTIC REGRESSION ANALYSIS; NEUROLOGIC DISEASE; NONCIRRHOTIC PORTAL HYPERTENSION; PORTAL HYPERTENSION; PRESCRIPTION; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROBABILITY;

ANTI-HIV AGENTS; DIDANOSINE; HUMANS; HYPERTENSION, PORTAL;

EID: 79951596556     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq079     Document Type: Letter

References (10)

1. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009;49:626-635.
2. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples sparse data in conditional logistic regression analysis. Am J Epidemiol 2000;151:531-539. (Pubitemid 30471029)
3. Robins JM, Hernan MA, Brumback B. Marginal structural models causal inference in epidemiology. Epidemiology 2000;11:550-560. (Pubitemid 30660034)
4. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-570. (Pubitemid 30660035)
5. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
6. Greenland S. Small-sample bias corrections for conditional maximum-likelihood oddsratio estimators. Biostatistics 2000;1:113-122. (Pubitemid 33213525)
7. Greenland S, Christensen R. Data augmentation priors for Bayesian semi-Bayes analyses of conditional-logistic and proportional-hazards regression. Stat Med 2001;20:2421-2428. (Pubitemid 32782711)
8. Greenland S. Prior data for non-normal priors. Stat Med 2007;26:3578-3590. (Pubitemid 47180699)
9. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002;137:693-695. (Pubitemid 35176104)
10. US Food and Drug Administration. FDA drug safety communication: serious liver disorder associated with the use of Videx/Videx EC (didanosine) Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm199169.htm. Accessed 31 August 2010.